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Genome-wide association studies in the Japanese
population identify seven novel loci for type 2
diabetes
Minako Imamura et al.#
Genome-wide association studies (GWAS) have identiﬁed more than 80 susceptibility loci
for type 2 diabetes (T2D), but most of its heritability still remains to be elucidated. In this
study, we conducted a meta-analysis of GWAS for T2D in the Japanese population.
Combined data from discovery and subsequent validation analyses (23,399 T2D cases and
31,722 controls) identify 7 new loci with genome-wide signiﬁcance (Po5 10 8), rs1116357
near CCDC85A, rs147538848 in FAM60A, rs1575972 near DMRTA1, rs9309245 near ASB3,
rs67156297 near ATP8B2, rs7107784 near MIR4686 and rs67839313 near INAFM2. Of these,
the association of 4 loci with T2D is replicated in multi-ethnic populations other than
Japanese (up to 65,936 T2Ds and 158,030 controls, Po0.007). These results indicate that
expansion of single ethnic GWAS is still useful to identify novel susceptibility loci to complex
traits not only for ethnicity-speciﬁc loci but also for common loci across different ethnicities.
Correspondence and requests for materials should be addressed to S.M. (email: smaeda@med.u-ryukyu.ac.jp) or to T.K. (email: kadowaki-3im@h.u-tokyo.ac.jp).
#A full list of authors and their afﬁliations appears at the end of the paper.
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T
o date, more than 80 susceptibility loci for type 2 diabetes
(T2D) have been identiﬁed through genome-wide associa-
tion studies (GWAS)1–18. However, the joint effects of
these variants account for o10% of the heritability for T2D10,19.
GWAS for T2D have been extensively conducted in populations
of European descent and, accordingly, the majority of established
T2D susceptibility genetic loci were originally identiﬁed by
European GWAS1,2,8–11,16. Cumulative evidence suggests that
Asian populations may be more genetically susceptible to T2D
than populations with European ancestry20. In addition, there are
signiﬁcant interethnic differences in the risk allele frequency or in
effect sizes at several loci, which may affect the power to detect
associations in these populations2. On the other hand, both
overlap in T2D susceptibility loci among different ancestry
groups and coincident risk alleles at lead single-nucleotide
polymorphisms (SNPs) across diverse populations have been
reported, suggesting that causal variants at many of these loci are
shared across different ancestry groups12. Moreover, a recently
published transethnic GWAS has successfully identiﬁed seven
novel T2D susceptibility loci by combining the association data
from European, South Asian, East Asian and Mexican/Latinos
GWAS12. Therefore, it is valuable to perform GWAS for
T2D using non-European and European populations, to
facilitate identiﬁcation of both ethnicity-speciﬁc and common-
susceptibility loci among different ethnic groups.
Four T2D GWAS loci discovered in a Japanese population
earlier have been shown to be signiﬁcantly associated with
T2D in the largest European GWAS meta-analysis10: KCNQ1
(refs 3,4), UBE2E2 (ref. 5), C2CD4A–C2CD4B5 and ANK1 (ref. 6),
highlighting that there are common loci conferring susceptibility
to T2D among the different ethnic groups studied.
Three additional loci (MIR129-LEP, GPSM1 and SLC16A11-
SLC16A13) have been identiﬁed by a large-scale Japanese GWAS
(n¼B25,000) based on the imputation of genotypes using the
1000 Genomes Project data as a reference7. One of the ﬁndings,
the association in the SLC16A11–SLC16A13 was also conﬁrmed
in the Mexican GWAS study15.
To identify novel loci for susceptibility to T2D, we have
expanded the Japanese GWAS data set by incorporating new
Japanese GWAS data (9,817 T2D cases and 6,763 controls) with
GWAS data in previously reported case–control individuals
(5,646 T2D cases and 19,420 controls)7 followed by a validation
study using independent Japanese case–control individuals (7,936
T2D and 5,539 controls) and multi-ethnic replication studies
(East Asians: 12,554 T2D and 17,383 controls; Europeans: 38,947
T2D and 121,903 controls; South Asians: 10,587 T2D and 14,378
controls; and Mexian/Latinos: 3,848 T2D and 4,366 controls). As
a result, we identify seven novel loci for T2D and the result
indicates that expansion of single ethnic GWAS is still useful to
identify novel susceptibility loci to complex traits.
Results
GWAS meta-analysis and validation in the Japanese population.
Imputed genotype dosage data for 9,817 T2D cases and 6,763
controls for 7,521,072 autosomal SNPs (Stage-1, set-1) were
obtained and combined with an independent GWAS data of
previously reported case–control individuals7 (Stage-1, set-2:
5,646 T2D cases and 19,420 controls; 7,521,072 autosomal SNPs),
as shown in Fig. 1a. There was no obvious inﬂation
in the quantile–quantile plots for each study (Stage-1:
lGC¼ 1.13 and lGC adjusted for 1,000 cases and controls
(lGC-1000)21¼ 1.012; Stage-2: lGC¼ 1.082 and lGC-1000¼ 1.009),
as shown in Supplementary Fig. 1A,B. SNPs with a low
imputation quality (r2o0.7 either in set-1 or set-2) or with an
inconsistent direction of effect between the studies were excluded
from the analysis. We obtained 42 loci exhibiting a suggestive
association with T2D (Po1 10 6). The most signiﬁcant
association in this meta-analysis was rs2237896 located at
intron 15 of KCNQ1 (P¼ 2.81 10 70), which was previously
identiﬁed in Japanese GWAS3,4 (Supplementary Fig. 1C). Out of
the 42 loci, 25 were previously established T2D susceptibility loci
(Supplementary Table 1) and the remaining 17 were further
evaluated using an independent Japanese case–control study
(Stage-2: 7,936 T2D cases and 5,539 controls, multi-centre) and
de novo genotyping (Supplementary Tables 2 and 3).
To explore the novel T2D susceptibility loci, we combined the
association data for the candidate SNPs from all the Japanese
case–control samples (Stage-1 set-1, Stage-1 set-2 and Stage-2)
using a meta-analysis (Fig. 1b and Supplementary Table 3) and
identiﬁed seven T2D susceptibility loci with a signiﬁcant
association (Po5 10 8; Table 1, Fig. 2 and Supplementary
Table 3): rs1116357 near CCDC85A (P¼ 6.97 10 10, odds
ratio (OR)¼ 1.09, 95% conﬁdence interval (CI)¼ 1.06–1.12),
rs147538848 in FAM60A (P¼ 7.83 10 10, OR¼ 1.11, 95%
CI¼ 1.07–1.15), rs1575972 near DMRTA1 (P¼ 1.50 10 9,
OR¼ 1.19, 95% CI¼ 1.13–1.26), rs9309245 near ASB3 (P¼ 1.25
 10 8, OR¼ 1.10, 95% CI¼ 1.07–1.14), rs67156297 near
ATP8B2 (P¼ 1.95 10 8, OR¼ 1.14, 95% CI¼ 1.09–1.19),
rs7107784 near MIR4686 (P¼ 2.07 10 8, OR¼ 1.14, 95%
CI¼ 1.09–1.20) and rs67839313 near INAFM2 (P¼ 2.42 10 8,
OR¼ 1.09, 95% CI¼ 1.06–1.12). The effect sizes (OR) of these
seven SNPs were similar before and after adjusting for age, sex
and body mass index (BMI) (Supplementary Table 4). The
rs1575972 locus in DMRTA1 was located 170 kbp away from the
T2D locus CDKN2A/B at 9p21 (refs 10,22–24) and the rs7107784
locus near MIR4686 was located B620 kbp upstream of KCNQ1
(refs 3,4). The linkage disequilibrium (LD) between rs1575972
and rs10811661, which was a lead SNP within the CDKN2A/B
locus10, was weak (JPT: r2¼ 0.01, CEU: r2¼ 0.02). The
association of rs1575972 was signiﬁcant even after conditioning
on rs10811661 (P for meta-analysis¼ 2.45 10 9, OR¼ 1.19,
95% CI¼ 1.12–1.26; Supplementary Table 5); therefore, we
considered the rs1575972 locus as a novel T2D susceptibility
locus, independent of the CDKN2A/B locus. We also observed
that the rs7107784 locus near MIR4686 was not in LD with
rs2237897 (JPT: r2o0.01, CEU: r2o0.01), which was a lead SNP
within the KCNQ1 locus3, and the association was similar after
conditioning on rs2237897 (P for meta-analysis¼ 2.75 10 8,
OR¼ 1.16, 95% CI¼ 1.10–1.22; Supplementary Table 6).
We also examined the association of these seven SNPs with
glycaemic traits in Stage-2 control individuals, including fasting
plasma glucose, homeostasis model assessment (HOMA) of b-cell
function (HOMA-b) and HOMA of insulin resistance (IR).
However, we did not detect any signiﬁcant associations between
the T2D risk alleles and these glycaemic traits (PZ0.0024
Supplementary Table 7). We also searched the publicly
available European GWAS data11,25,26 (MAGIC, http://
www.magicinvestigators.org) and found that the T2D risk allele
at the DMRTA1 locus (rs11791293-C; proxy for rs1575972-T,
CEU r2¼ 1) and at the MIR4686 locus (rs7111341-T; proxy for
rs7107784-G, CEU r2¼ 0.95) were associated with a decrease in
fasting plasma insulin (FPI) (P¼ 0.0039; Supplementary Table 8)
and with an increase in FPI (P¼ 0.0066; Supplementary Table 8),
respectively, although these associations were not statistically
signiﬁcant (PZ0.0008¼ 0.05/63 (7 SNPs 9 traits)).
Examination of seven novel loci in diverse ethnic groups. We
analysed the association of these seven variants with disease
susceptibility in populations other than Japanese. We obtained
association data for four ethnic groups using de novo genotyping,
in silico replication and by examining publicly available GWAS
data10 including East Asian (n¼ up to 29,937: 12,554 T2Ds and
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17,383 controls), South Asian (n¼ up to 24,965: 10,587 T2Ds and
14,378 controls), European (n¼ up to 160,850: 38,947 T2Ds and
121,903 controls) and Mexican (n¼ up to 8,214: 3,848 T2Ds
and 4,366 controls) populations (Supplementary Table 9).
Meta-analyses of the combined data from the four non-Japanese
ethnicities indicated that four SNP loci, namely rs147538848 in
FAM60A, rs1575972 near DMRTA1, rs7107784 near MIR4686
and rs67839313 near INAFM2 were associated with the disease
after Bonferroni’s correction (Po0.00714¼ 0.05/7; Table 2). The
disease association of these four SNPs was further corroborated
by combining the Japanese data with the multi-ethnic replication
data sets (Supplementary Table 10). The rs67156297 locus in
ATP8B2 was nominally associated with T2D in the combined
meta-analysis for multi-ethnic groups other than the Japanese
populations. We did not detect any disease association for the
remaining two SNP loci other than in the Japanese population;
however, the effect direction for each of the seven loci was
consistent with that in the Japanese population.
Sex- and BMI-stratiﬁed analyses in the Japanese population.
We performed BMI-stratiﬁed (BMIo25 orZ25) and sex-
stratiﬁed analyses in the novel and established GWAS loci,
to determine whether signiﬁcant heterogeneity in allelic effects
existed between non-obese and obese individuals or males and
females in the Japanese population. BMI-stratiﬁed analysis for
83 previously established loci revealed evidence of signiﬁcant
heterogeneity in the effect size between non-obese and obese
individuals at KCNQ1 (P for heterogeneity¼ 8.89 10 5;
Supplementary Table 11). The effect size of KCNQ1 was greater
in the non-obese group than in the obese group (Supplementary
Table 11). In sex-stratiﬁed analyses, individual established loci did
not show signiﬁcant heterogeneity in effect sizes between men
and women (P46 10 4; Supplementary Table 12).
For the seven novel T2D-associated loci identiﬁed in this study,
no signiﬁcant heterogeneity was detected in BMI-stratiﬁed or
sex-stratiﬁed analyses (Supplementary Tables 13 and 14).
Fine mapping analyses for established T2D loci. We examined
the association data of 83 previously identiﬁed T2D susceptibility
loci in the Japanese GWAS meta-analysis data (Supplementary
Data 1 and Supplementary Fig. 2). Variants at 19 loci were found
associated with T2D at a genome-wide level of signiﬁcance
and additional 30 loci were determined to be signiﬁcantly
associated with T2D (Po6.02 10 4¼ 0.05/83). Of the above
Meta-analysis
Inverse variance method
Case   15,463
Control  26,183
7,521,072 SNPs
Association for type 2 diabetes :  P < 1 × 10–6
Imputation accuracy : RSQ ≥0.7 
Consistent direction of the effect
between the studies
17 Loci , 248 SNPs
Established type 2 diabetes loci
( 25 loci  2,248 SNPs) 42 Loci 2,496 SNPs
Case  n =7,936  Control n =5,539
Stage-2 (de novo genotyping)
Lead SNPs in novel loci  17 SNPs
Stage-1, set-1 ; Japanese
Stage-1, set-2 ; Japanese
Stage-2           ; Japanese
Meta-analysis
P < 5 ×10–8
7 Novel loci
Replication study East Asian other than Japanese
South Asian
European
Mexican/latino
a
b
Case n =9,817, Control n =6,763
(Biobank Japan, Hondo cluster)
7,521,072 SNPs (imputed)
480,426 Autosomal SNPs (Illumina 610 K array)
Genome-wide association test
535,686 Autosomal SNPs (Omni express exome)
Imputation
Software: MACH and Minimac
Reference: 1000genome n =275, JPT+CHB+CHS
MAF ≥ 0.01, HWE P ≥ 1 × 10–6
7,521,072 SNPs (imputed)
Stage-1, set-1
Case n =5,646, Control n =19,420
(Biobank Japan, Hondo cluster)
Imputation
Software: MACH and Minimac
Reference: 1000genome n =275, JPT+CHB+CHS
MAF ≥ 0.01, HWE P ≥ 1 × 10–6
Genome-wide association test
Stage-1, set-2
Figure 1 | Outline of the present study. (a) GWAS meta-analysis and subsequent validation analysis. (b) Follow-up analyses for seven novel susceptibility
loci for T2D in populations other than Japanese. SNP, single nucleotide polymorphism; MAF, minor allele frequency; HWE P, Hardy-Weinberg Equilibrium
test P; RSQ, r square.
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49 signiﬁcant associations, ADCY5, HNF1A and PRC1 were not
previously evaluated in the Japanese population, because the lead
SNPs within these loci in the European GWAS (rs11708067 and
rs11717195 at the ADCY5 locus9,10, rs12427353 and rs7957197 at
the HNF1A locus8,10 and rs8042680 at the PRC1 locus8) were
monoallelic in the Japanese population. In this study, rs79223353
at the ADCY5 locus, rs55783344 at the HNF1A locus and
rs79548680 at the PRC1 locus were determined to be signiﬁcantly
associated with T2D (Po6.02 10 4; Supplementary Data 1
and Supplementary Fig. 3). Meta-analysis combining the GWAS
data with de novo genotyping data for Stage-2 individuals
revealed that the association of rs79223353 within the ADCY5
locus and rs79548680 within the PRC1 locus reached genome-
wide signiﬁcance in the Japanese population (Supplementary
Table 15). We did not detect any disease-associated SNPs within
the 16 loci (9 derived from European GWAS, 3 from East Asian,
2 from trans-ethnic, 1 from South Asian and 1 from African
American, PZ0.05) using ﬁne mapping analyses (Supplementary
Data 1 and Supplementary Fig. 2). We also identiﬁed a secondary
association signal located at EXOC6 near the IDE-HHEX locus10.
The associations of rs78627331 and rs34773007 within the
EXOC6 locus were signiﬁcant after conditioning on rs1111875
(r2¼ 0.01 for rs78627331 and r2¼ 0.04 for rs34773007 in JPT),
which was a previously reported lead SNP within the IDE-HHEX
locus (P¼ 1.49 10 8 for rs78627331, P¼ 2.20 10 8 for
rs34773007; Supplementary Table 16).
Drug targets search by a bioinformatics approach. We applied
the genetic information from previously reported and the present
GWAS, to investigate potential drug targets for the treatment of
T2D. First, we deﬁned 286 T2D potential risk genes located in any
of the 90 T2D risk loci (7 novel T2D loci that were identiﬁed in the
present study and 83 previously identiﬁed T2D loci; see
INAFM2 →
CCDC85A FAM60A DMRTA1
ASB3 MIR4686ATP8B2
INAFM2
CCDC85A→ VRK2 →
←ASB3 ←PSME4
←
CHAC2→
ERLEC1→
←MIR3682
←GPR75
PAK6 → ←PLCB2 DISP2 → KNSTRN→ IVD→←C15orf52
PHGR1→←C15orf56 ←ANKRD63
TSPAN11→ DDX11 → METTL20→←FAM60A ←DENND5B
FLJ13224→ →←
←AMN1
←SLC39A1 ←TPM3
CREB3L4→ ←MIR190B
HAX1→ TDRD10→IL6R → ←KCNN3
AQP10 → CHRNB2→
ATP8B2→
←SHE
←JTB
RPS27→
←C1orf189
UBAP2L→
←UBE2Q1
←RAB13 ←C1orf43
←NUP210L
←ADAR
SYT8→ ←TNNT3 → CD81→ KCNQ1→
TNNI2→ MRPL23→
LSP1→
←ASCL2
←IGF2 ←C11orf21
←MIR483
TSSC4 →
→
TSPAN32 →
MIR4686 →
←
←MIR4298
←TRPM5
← MIR675
←H19
←INS
←TH
DMRTA1→
CDKN2B-AS1→
← CDKN2B
← CDKN2A
C9orf53 → FLJ35282 →0
2
4
6
8
00
2
4
6
8
10
0
2
4
6
8
10
Position on chr2(Mb)
56.5 57 57.5 58
Position on chr12(Mb)
31.2 31.4 31.6 31.8
Position on chr2(Mb)
53 53.5 54
Position on chr1(Mb)
154 154.2 154.4 154.6
Position on chr15(Mb)
40.55 40.6 40.65 40.7
Position on chr11(Mb)
2 2.2 2.4 2.6
Position on chr9(Mb)
22 22.2 22.4 22.6
rs1116357 rs147538848 rs1575972
rs7107784rs67156297rs9309245
rs67839313
r 2
0.8
0.6
0.4
0.2
r 2
0.8
0.6
0.4
0.2
r 2
0.8
0.6
0.4
0.2
r 2
0.8
0.6
0.4
0.2
r 2
0.8
0.6
0.4
0.2
r 2
0.8
0.6
0.4
0.2
r 2
0.8
0.6
0.4
0.2
–
Lo
g 1
0(P
-
va
lu
e)
–
Lo
g 1
0(P
-
va
lu
e)
0
2
4
6
8
10
–
Lo
g 1
0(P
-
va
lu
e)
–
Lo
g 1
0(P
-
va
lu
e)
0
2
4
6
8
10
–
Lo
g 1
0(P
-
va
lu
e)
0
2
4
6
8
10
–
Lo
g 1
0(P
-
va
lu
e)
–
Lo
g 1
0(P
-
va
lu
e)
10
0
20
40
60
80
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)100
0
20
40
60
80
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)
100
0
20
40
60
80
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)
100
0
20
40
60
80
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)
100
0
20
40
60
80
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)100
0
20
40
60
80
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)100
0
20
40
60
80
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)100
30
20
10
*Gene position for INAFM2
was added manually 
GPR75-ASB3
INS-IGF2
IGF2-AS
MRPL23-AS1
DDX11-AS1 DENND5B-AS1
a b c
d e f
g
Figure 2 | Regional association plots of the two-stage GWAS meta-analysis for seven novel T2D susceptibility loci in the Japanese. Each plot shows
 log10 P-values against the chromosomal positions of SNPs in the speciﬁc region. The SNP with the strongest association signal (lead SNP) in each locus
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Supplementary Note). Among the 286 genes, by using a previously
described scoring system27, we selected 40 genes with a score of 2
or higher (Supplementary Note, Supplementary Tables 17–20,
Supplementary Data 2 and 3, and Supplementary Figs 4 and 5) as
‘biological T2D risk genes’ (Fig. 3 and Supplementary Data 4). In
brief, we scored each of the 286 biological candidate genes by
adopting the following six selection criteria and calculating the
number of satisﬁed criteria as follows: (1) genes for which T2D risk
SNPs or any of the SNPs in LD (r2Z0.80) with them were
annotated as missense variants; (2) genes for which cis-eQTL genes
of any of lymphoblastoid cell lines, adipose tissue or liver tissues
were observed for T2D risk SNPs (Po0.05 for lymphoblastoid cell
lines and adipose tissues, and Po0.004 for liver tissues); (3)
monogenic diabetes genes; (4) genes for which at least three out of
six associated phenotype labels (homeostasis/metabolism, liver/
biliary system, endocrine/exocrine gland, growth/size/body,
mortality/ageing and embryogenesis; Po9.2 10 5) were
observed in knockout mouse28; (5) genes prioritized by PubMed
text mining genes using GRAIL29 with gene-based Po0.05; and (6)
genes prioritized by protein–protein interaction (PPI) network
using DAPPLE30 with gene based Po0.05.
As these criteria exhibited weak correlations with each other
(r2o0.34; Supplementary Fig. 5), each gene was given a score
based on the number of criteria that were met (scores ranged
from 0 to 6). Genes with a score of 2 or higher were deﬁned as
biological T2D risk genes.
We searched for overlapping genes between the 871 drug target
genes corresponding to approved, in clinical trials or experimental
drugs for various human diseases described in the previous
report27, and the 40 biological T2D risk genes plus 712 genes
that are known to have products that have direct PPI30 with the
biological T2D risk gene products. We identiﬁed a total of 83
overlapping genes (Supplementary Fig. 6 and Supplementary
Table 21). Fourteen drug target genes with approved T2D
treatments demonstrated signiﬁcant overlap with the 40 biological
T2D risk genes and 712 genes with direct PPI (4 genes overlapped
with 5.6-fold enrichment as determined using permutation analysis,
P¼ 0.0042; Supplementary Table 22 and Supplementary Fig. 6).
The 871 drug target genes had overlap with the identiﬁed 83 genes,
which is 1.8-fold more enrichment than would be expected by
chance, but this is 3.1-fold less enrichment compared with overlap
of the targets of T2D drugs (Supplementary Fig. 6).
Of the 83 overlapping genes, 5 were biological T2D risk genes
(PPARG, KCNJ11, ABCC8, GCK and KIF11; Fig. 4). Three of
these are targets of approved T2D drug treatments: PPARG,
thiazolidinediones; KCNJ11, sulfonylurea; ABCC8, sulfonylureas
and glinide. GCK is a target gene of a GCK activator that was in
clinical trials as of August 2014 (Supplementary Table 23). Of the
remaining 78 genes, 2 genes exhibit PPI with 3 biological T2D
risk gene products. GSK3B interacts with NOTCH1, NOTCH2
and CCND2, whereas JUN interacts with FBXW7, HHEX and
CCND2. Eight genes interact with 2 biological T2D risk gene
products and 68 genes interact with a single biological T2D risk
gene product (Supplementary Table 21). A list of therapeutic
drugs that are currently under clinical trials targeting GCK,
KIF11, GSK3B and JUN is shown in Supplementary Table 23.
Discussion
In this study, we performed a GWAS meta-analysis in the
Japanese population followed by validation using an independent
Japanese sample. Integration of the results for B55,000 Japanese
individuals identiﬁed 7 novel loci associated with T2D that
Table 1 | Newly identiﬁed T2D susceptibility loci achieving genome-wide signiﬁcance (combined meta-analysis Po5 108) in
Japanese populations.
SNP ID Chr. Position (Build 37) Alleles Study RAF OR (95% CI) P-value Phet
nearby gene Risk Other Case Control
rs1116357 G A Stage-1, set-1 0.292 0.269 1.12 (1.07–1.17) 6.55 10 6
2 Stage-1, set-2 0.299 0.279 1.10 (1.05–1.15) 2.61 10 5
57287411 Stage-2 0.294 0.284 1.05 (0.99–1.11) 8.65 10 2
CCDC85A Combined 1.09 (1.06–1.12) 6.97 10 10 0.21
rs147538848 A G Stage-1, set-1 0.205 0.190 1.11 (1.05–1.18) 5.81 104
12 Stage-1, set-2 0.199 0.184 1.12 (1.06–1.18) 1.15 104
31466613 Stage-2 0.210 0.193 1.11 (1.04–1.18) 1.10 10 3
FAM60A Combined 1.11 (1.07–1.15) 7.83 10 10 0.99
rs1575972 T A Stage-1, set-1 0.947 0.935 1.24 (1.13–1.36) 8.64 106
9 Stage-1, set-2 0.943 0.935 1.17 (1.07–1.29) 1.13 10 3
22301092 Stage-2 0.950 0.942 1.16 (1.04–1.29) 7.60 10 3
DMRTA1 Combined 1.19 (1.13–1.26) 1.50 10 9 0.62
rs9309245 G C Stage-1, set-1 0.178 0.164 1.10 (1.04–1.17) 1.57 10 3
2 Stage-1, set-2 0.186 0.168 1.14 (1.08–1.20) 3.43 10 6
53397048 Stage-2 0.181 0.172 1.06 (0.998–1.14) 5.95 10 2
ASB3 Combined 1.10 (1.07–1.14) 1.25 108 0.30
rs67156297 A G Stage-1, set-1 0.102 0.086 1.21 (1.12–1.30) 1.28 106
1 Stage-1, set-2 0.097 0.087 1.13 (1.05–1.21) 1.34 10 3
154336716 Stage-2 0.092 0.087 1.07 (0.98–1.16) 1.33 10 1
ATP8B2 Combined 1.14 (1.09–1.19) 1.95 108 0.10
rs7107784 G A Stage-1, set-1 0.099 0.089 1.16 (1.07–1.26) 4.91 104
11 Stage-1, set-2 0.101 0.090 1.18 (1.09–1.27) 3.88 10 5
2215089 Stage-2 0.093 0.086 1.09 (0.998–1.19) 5.58 10 2
MIR4686 Combined 1.14 (1.09–1.20) 2.07 108 0.42
rs67839313 C T Stage-1, set-1 0.280 0.261 1.10 (1.05–1.16) 7.87 10 5
15 Stage-1, set-2 0.278 0.264 1.08 (1.03–1.14) 1.75 10 3
40619724 Stage-2 0.281 0.267 1.07 (1.01–1.13) 1.36 10 2
INAFM2 Combined 1.09 (1.06–1.12) 2.42 108 0.73
CI, conﬁdence interval; Chr., chromosome; OR, odds ratio; Phet, P-value for Cochran’s Q-test for heterogeneity; RAF, risk allele frequency; SNP, single-nucleotide polymorphism.
Alleles are aligned to the forward strand of NCBI Build 37.
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reached genome-wide signiﬁcance. In a subsequent transethnic
meta-analysis, four loci were conﬁrmed and one locus was
suggested as common susceptibility loci for T2D in populations
other than the Japanese population.
GWAS have been extensively performed in diverse ethnic
groups, including populations of European, East Asian, South
Asian and Mexican decent1–18. To this point, the sample size of
GWAS for European populations has grown to over 100,000
(ref. 10) and these studies have identiﬁed nearly 50 loci associated
with T2D. GWAS on populations of non-European origin and
transethnic GWAS meta-analysis have identiﬁed more than 30
loci associated with T2D, which were not detected in earlier
European GWAS3–7,12–15,18. Among these, several loci have
been shown to be associated with T2D in larger European
populations10, which suggests that further expansion of GWAS
for non-European populations could prove useful in identifying
additional susceptibility loci associated with T2D.
Among the seven novel loci identiﬁed in this study,
rs147538848 in FAM60A, rs1575972 near DMRTA1, rs7107784
near MIR4686 and rs67839313 near INAFM2 were shown to be
common susceptibility loci for T2D across different ethnicities,
although the signiﬁcance of the association differed among
individual ethnic groups for several loci.
rs147538848 is located in the intron of FAM60A, which
encodes a subunit of the Sin3 deacetylase complex (Sin3/HDAC1)
that has been shown to be important for the repression of genes
encoding components of the transforming growth factor-b
signalling pathway31. Studies using a rat intrauterine growth
retardation model have suggested that the Sin3/HDAC1 complex
may negatively regulate the expression level of pancreatic and
Table 2 | Association of novel seven SNP loci with type 2 diabetes risk in the population other than Japanese.
SNP ID Alleles Population OR (95% CI) P-value Phet RAF*
Risk Other
rs1116357 G A All replication setw 1.01 (0.99–1.03) 1.99 10 1 0.96
CCDC85A East Asian 1.03 (0.99–1.07) 2.06 10 1 0.98 0.28
South Asian 1.02 (0.98–1.05) 4.18 10 1 0.34 0.57
European 1.01 (0.98–1.04) 5.45 10 1 0.98 0.53
Mexican/Latino 0.99 (0.93–1.05) 5.96 10 1 NA 0.48
All Japanese 1.09 (1.06–1.12) 6.97 10 10 0.21 0.28
rs147538848 A G All replication set 1.10 (1.05–1.16) 2.25 104 0.82
FAM60A East Asian 1.13 (1.05–1.20) 3.58 104 0.88 0.19
South Asian 1.07 (0.97–1.17) 1.59 10 1 0.35 0.06
European NA NA NA 0.01
Mexican/Latino 1.01 (0.74–1.37) 8.98 10 1 NA 0.01
All Japanese 1.11 (1.07–1.15) 7.83 10 10 0.99 0.23
rs1575972 T A All replication set 1.13 (1.08–1.18) 2.26 10 7 0.13
DMRTA1 East Asian 1.14 (1.02–1.26) 1.62 10 2 0.03 0.96
South Asian 1.13 (1.03–1.24) 1.21 10 2 0.45 0.94
European 1.14 (1.07–1.21) 5.58 10 5 0.56 0.97
Mexican/Latino 1.004 (0.83–1.21) 9.92 10 1 NA 0.98
All Japanese 1.19 (1.13–1.26) 1.50 109 0.62 0.93
rs9309245 G C All replication set 1.01 (0.99–1.03) 5.50 10 1 0.58
ASB3 East Asian 1.04 (0.99–1.09) 1.64 10 1 0.40 0.20
South Asian 0.996 (0.96–1.04) 8.21 10 1 0.63 0.31
European 1.01 (0.98–1.04) 4.74 10 1 0.80 0.35
Mexican/Latino 0.96 (0.90–1.03) 2.31 10 1 NA 0.26
All Japanese 1.10 (1.07–1.14) 1.25 10 8 0.30 0.17
rs67156297 A G All replication set 1.03 (1.001–1.05) 4.08 10 2 0.38
ATP8B2 East Asian 1.05 (0.99–1.12) 1.22 10 1 0.26 0.09
South Asian 0.98 (0.94–1.03) 4.79 10 1 0.99 0.20
European 1.04 (0.999–1.08) 5.90 10 2 0.88 0.25
Mexican/Latino 1.08 (0.995–1.18) 8.19 10 2 NA 0.16
All Japanese 1.14 (1.09–1.19) 1.95 10 8 0.10 0.10
rs7107784 G A All replication set 1.05 (1.03–1.08) 7.05 10 7 0.0079
MIR4686 East Asian 1.001 (0.91–1.10) 9.83 10 1 0.010 0.12
South Asian 1.09 (1.03–1.15) 1.60 10 3 0.20 0.25
European 1.04 (1.02–1.07) 4.39 104 0.43 0.28
Mexican/Latino 1.15 (1.05–1.25) 6.00 104 NA 0.16
All Japanese 1.14 (1.09–1.20) 2.07 10 8 0.42 0.08
rs67839313 C T All replication set 1.05 (1.02–1.07) 2.91 104 0.41
INAFM2 East Asian 1.09 (1.04–1.15) 1.93 104 0.50 0.25
South Asian 1.03 (0.99–1.08) 1.68 10 1 0.77 0.32
European 1.02 (0.98–1.06) 3.61 10 1 0.18 0.11
Mexican/Latino 1.06 (0.97–1.14) 1.16 10 1 NA 0.19
All Japanese 1.09 (1.06–1.12) 2.42 10 8 0.73 0.27
CI, conﬁdence interval; OR, odds ratio; Phet, P-value for Cochran’s Q-test for heterogeneity; RAF, risk allele frequency; SNP, single-nucleotide polymorphism.
Alleles are aligned to the forward strand of NCBI Build 37.
*Risk allele frequency in each populations. Data are from 1000 Genomes Project Phase 3 allele frequencies (ASN, SAS, EUR, MXL and JPT).
wConbined association data from 21 studies (11 East Asian other than Japanese, 6 South Asian, 3 European and one Mexican/Latino).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10531
6 NATURE COMMUNICATIONS | 7:10531 | DOI: 10.1038/ncomms10531 | www.nature.com/naturecommunications
duodenal homeobox 1 (PDX1), which is known as an important
transcription factor for the development of pancreas and b-cell
maturation32 via histone modiﬁcation of its proximal promoter33.
A T2D risk allele at the FAM60A locus might contribute to
disease susceptibility by impairing the transcriptional regulation
of genes that are important for glucose metabolism.
INAFM2 encodes InaF-motif containing 2 and has previously
been known as Osteogenesis upregulated transcript 1 (OGU1) or
long intergenic non-protein coding RNA 984 (LINC00984),
which is a putative long non-coding RNA. Although the
expression of OGU1 has been shown to be upregulated during
osteogenesis34, the function of INAFM2 encoding protein is still
unknown. Around rs67839313, there are two plausible genes for
susceptibility to T2D: PLCB2 and DISP2. PLCB2 encodes
phospholipase C isoform b-2 and phospholipase C is a known
regulator of insulin secretion through hydrolysis of islet
phosphoinositide pools35. Therefore, it is feasible that this locus
is associated with impaired glucose-stimulated insulin secretion
machinery. DISP2 encodes dispatched homologue 2, which is a
cell surface marker on insulin-positive cells36. Although the
functional role of this molecule in glucose homeostasis is not well
understood, it is potentially involved in the maturation of
pancreatic b-cells or it might have a role in already matured
pancreatic b-cells.
The effect size for the T2D association of rs1575972 near
DMRTA1 was similar among all populations in this study, except
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rs10923931 1 NOTCH2 2
rs780094 2 GCKR 3
rs780094 2 NRBP1 2
rs780094 2 PPM1G 2
rs10203174 2 THADA 2
rs1801282 3 PPARG 5
rs1801282 3 SYN2 2
rs4458523 4 WFS1 5
rs6813195 4 FBXW7 3
rs702634 5 ARL15 2
rs35658696 5 PAM 3
rs9505118 6 SSR1 2
rs115164593 6 POU5F1 2
rs115164593 6 TCF19 2
rs10278336 7 GCK 3
rs10229583 7 PAX4 3
rs4731420 7 LEP 3
rs12549902 8 ANK1 2
rs7845219 8 TP53INP1 2
rs7845219 8 CCNE2 2
rs3802177 8 SLC30A8 2
rs7041847 9 GLIS3 4
rs28642252 9 GPSM1 2
rs28642252 9 INPP5E 2
rs28642252 9 NOTCH1 2
rs1802295 10 VPS26A 2
rs1802295 10 SUPV3L1 2
rs1111875 10 KIF11 2
rs1111875 10 HHEX 3
rs7903146 10 TCF7L2 2
rs5215 11 ABCC8 3
rs5215 11 KCNJ11 4
rs11063069 12 CCND2 2
rs12427353 12 HNF1A 4
rs4275659 12 SETD8 2
rs11634397 15 FAH 2
rs11651052 17 HNF1B 5
rs10401969 19 GATAD2A 2
rs10401969 19 TM6SF2 2
rs4812829 20 HNF4A 3
Biological gene criteria
Figure 3 | Prioritized biological T2D risk genes. The gene score for each gene was calculated by summing up the number of criteria satisﬁed (ﬁlled red
box indicates criterion satisﬁed; 40 genes with a scoreZ2 out of 286 genes included in the T2D risk loci were deﬁned as ‘biological candidate genes’; see
Supplementary Data 4). Filled blue boxes indicate the nearest gene to the T2D risk SNP. Filled green boxes indicate overlap with drug target genes.
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for the Mexican/Latino population (Table 2 and Supplementary
Table 10). The risk allele of rs1575972 in the DMRTA1 locus was
nominally correlated with a decrease in FPI (Supplementary
Table 8), which suggests that this locus might contribute to T2D
susceptibility through affecting insulin secretion in pancreatic
b-cells. The DMRTA1 encodes doublesex and mab-3-related
transcription factor-like family A1, which has been recently
reported to be involved in neuronal development by regulating
the Pax6-Neurog2 transcriptional cascade37. Although the
relevance of DMRTA1 to pancreatic development has not been
established, DMRTA1 might play a role in b-cell development,
because Pax6 and Neurog3, other member of the neurogenin
subfamily, are key transcriptional regulators of pancreatic
endocrine cell differentiation38.
INS, IGF-2 and TH are located at approximately rs7107784
near the MIR4686 locus. IGF-2 plays a key role in embryonic
growth and may also inﬂuence body weight in adulthood39, and
TH (tyrosine hydroxylase) has been shown to play a role in b-cell
development40. This locus is known to be associated with risk of
type-1 diabetes (rs1004446-C, 45 kbp from rs7107784; r2¼ 0.003,
D0 ¼ 0.275)41. The risk allele of rs7107784-G is nominally
associated with the increase of FPI levels in the European
population (MAGIC data; Supplementary Table 8) and an
increase of HOMA-IR in our Japanese data set (Supplementary
Table 7). This suggests that the effects of rs7107784-G are
probably not mediated by an impairment of insulin production or
secretion, but rather by an impairment of insulin sensitivity.
rs67156297 near ATP8B2 was nominally associated with T2D
in the transethnic replication meta-analysis (Table 2 and
Supplementary Table 10). ATP8B2 encodes a member of the P4
family of ATPases (type 4P-type ATPase), which are multispan
transmembrane proteins that have been implicated in phospho-
lipid translocation from the exoplasmic to the cytoplasmic
membrane leaﬂet42. The role of ATP8B2 in the pathogenesis of
T2D has not been established. However, another member of the
P4 ATPase family, atp10a, has been shown to be important for
the biogenesis and/or membrane-directed trafﬁcking of Glut4
receptors, and loss-of-function of atp10a induces IR and obesity
in mice42.
The remaining two loci, rs1116357 near CCDC85A and
rs9309245 near ASB3, were not associated with T2D (P40.05) in
the replication meta-analysis for non-Japanese populations, which
suggests that the effect of these loci might be speciﬁc to the Japanese
population. As heterogeneity in effect sizes was observed for
rs1116357 or rs9309245 between Japanese and other ethnic groups,
including European, South Asian and Mexican (Supplementary
Tables 25 and 27), two possibilities might exist for the two SNP loci:
(1) the LD between the causal alleles and the Japanese lead SNPs
are consistent across the populations, but the risk alleles have effects
only in the Japanese, and (2) the causal alleles are in LD with these
SNPs only in the Japanese. By a systematic evaluation for effect
sizes and LDs within these loci, we did not identify any SNPs
associated with T2D in European populations, which are in LD
with our lead SNPs in the Japanese, whereas not in LD in European
populations (Supplementary Fig. 8 and Supplementary Tables 26
and 27). Therefore, the causal allele in the two loci might have an
effect only in Japanese populations; however, further evaluation is
required to elucidate the precise mechanism how these loci
contribute to T2D susceptibility in the Japanese.
While searching for potential drug targets for T2D using a
systematic bioinformatics approach, 83 overlapping genes were
identiﬁed from 752 genes (40 biological T2D GWAS genes and
712 genes that encode products in direct PPI with 40 biological
T2D GWAS genes) and 871 drug target genes for various human
diseases27. Of these, 5 were T2D GWAS genes: PPARG, KCNJ11,
ABCC8, GCK and KIF11. PPARG, KCNJ11 and ABCC8 have
approved T2D treatment options. In addition, a GCK activator is
currently undergoing clinical trials for the treatment of T2D.
KIF11, which encodes kinesin family member 11 (also known as
EG5), has been shown to be involved in regulating cell mitosis
and inhibitors targeting this gene product have been developed as
chemotherapeutic agents in the treatment of cancer43. Although
the role of KIF11 in the regulation of glucose metabolism has not
been well established, a recent study reported that knockdown
of KIF11 using small interfering RNA resulted in increased
glycogenesis in human primary hepatocytes44. Thus, a KIF11
inhibitor might ameliorate glucose homeostasis by suppressing
gluconeogenesis from the liver.
T2D risk SNPs Biological genes
within the loci
Genes in 
direct PPI Targeted drugs Diseases
rs1801282
rs1111875
rs28642252
rs6813195
rs1111875
rs10923931
rs11063069
GSK3B
JUN
NOTCH1
NOTCH2 
CCND2
FBXW7
HHEX
rs10278336
rs5215
GCKRrs780094
KCNJ8
GCK
PPARG
ABCC8
KIF11
KCNJ11
Thiazolidinediones
Sulfonylureas
Glinides
Glucokinase activators *
KIF11 inhibitors *
GSK3B inhibitors *
AP-1 inhibitor *
Type 2 diabetes
Diseases other than
type 2 diabetes **
Figure 4 | Connection of biological T2D risk genes to drug targets. Representative connections between T2D risk SNPs (blue), T2D biological genes
(green), drug target genes (purple) and targeted drugs are shown (see Supplementary Table 21). *Compounds under clinical trial; **see Supplementary
Table 23.
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We identiﬁed two genes, GSK3B and JUN, which directly
interact with multiple biological T2D susceptibility genes. GSK3B
encodes glycogen synthase kinase 3b, which is a constitutively
active multifunctional serine/threonine kinase and is involved in
diverse physiological pathways, including metabolism, cell cycle
regulation, gene expression, development, oncogenesis and
neuroprotection45. Several studies using Gsk3b-modiﬁed mouse
models have suggested that inhibition of GSK3B function may
have beneﬁcial effects on glucose metabolism through pancreatic
b-cell preservation or enhancement of insulin-stimulated
glycogen synthase regulation and glycogen deposition45–47.
Currently, GSK3B inhibitors are under clinical trial for the
treatment of cancers (Supplementary Table 23), but these
compounds could also be potential treatments for T2D.
JUN encodes the proto-oncogene c-Jun and the role of c-Jun in
the pathogenesis of T2D is not well understood. However, c-Jun
has been shown to decrease the expression of the human insulin
gene by repressing insulin promoter activity48. c-Jun is a
transactivation component of the heterodimeric transcription
factor AP-1 and activated through phosphorylation of serines 63
and 73 by Jun N-terminal kinase 2 (ref. 49), and inhibition of JNK
has been shown to ameliorate glucose intolerance in a mouse
model for T2D50. Currently, AP-1 inhibitor is under clinical trial
for the treatment of rheumatoid arthritis (Supplementary
Table 23) and might also be potential treatments for T2D.
Although these results suggest that these loci are potential
therapeutic targets for treating T2D, the pipeline used to identify
these genes has some limitations. As eQTL effects have often been
observed for genes far from each locus, it is possible that some
biological genes located outside of LD block in each locus were
overlooked. In addition, the selection criteria for PubMed text-
mining or knockout mouse studies were based on the known
functions; therefore, T2D-associated genes whose functions have
not been established may have been missed. The number of criteria
that were met for individual genes were simply summed for
scoring, although the relative impact of the six criteria used here on
biological signiﬁcance may not be equal. We used the previously
described scoring method27, to prioritize genes in an objective
manner; however, it would be worthwhile to reﬁne the pipeline by
modifying the selection criteria for genes in future studies. Finally,
the potential therapeutic targets or treatments identiﬁed through
the in silico pipeline have not yet been validated through an
experimental approach. Furthermore, in vivo evaluation is essential
to clarify the therapeutic effect of these potential T2D treatments.
In conclusion, we have identiﬁed seven novel T2D susceptibility
loci using a large-scale Japanese GWAS meta-analysis. The T2D
association for four of these was also observed in non-Japanese
populations. In addition, we have proposed several new potential
pharmacological targets for T2D treatment using a systematic
bioinformatics approach. These results indicate that expansion of
single ethnic GWAS is still useful to identify novel susceptibility loci
to complex traits not only for ethnicity-speciﬁc but also for common
loci across different ethnicities. Moreover, systematic approaches for
integrating the ﬁndings of genetic, biological and pharmacological
studies could be useful for developing new T2D treatments,
although additional pipeline reﬁnement would be required.
Methods
Subjects. Discovery stage (Stage-1). We selected T2D cases from individuals regis-
tered in BioBank Japan as having T2D (set-1 cases, n¼ 9,817). Control groups
consisted of individuals registered in BioBank Japan as not having T2D but with
diseases other than T2D (cerebral aneurysm, oesophageal cancer, endometrial cancer,
chronic pulmonary emphysema or glaucoma) or volunteers from the Osaka-Mid-
osuji Rotary Club and Pharma SNP consortium (set-1 controls, n¼ 6,763;
Supplementary Table 24). We also used case and control individuals registered in the
BioBank Japan that were previously analysed and reported (set-2 cases, n¼ 5,646 and
set-2 controls, n¼ 19,420)7. There was no overlap in individuals in set-1 and set-2.
Validation analysis (Stage-2). We examined 7,936 T2D cases from the BioBank
Japan that were not included in the discovery stage and from subjects with T2D,
who visited outpatient clinics at The University of Tokyo, Juntendo University,
National Center for Global Health and Medicine, Hiranuma Clinic, St Marianna
University School of Medicine, The Hiroshima Atomic Bomb Casualty Council
Health Management Center, Kawasaki Medical School, Toyama University
Hospital or Shiga University of Medical Science. We also examined 5,539 controls
from individuals that enrolled during an annual health check-up at six institutions:
The Hiroshima Atomic Bomb Casualty Council Health Management Center,
The National Center for Global Health and Medicine, Keio University, Hiranuma
Clinic, St Marianna University School of Medicine and Toyama University
Hospital. T2D was diagnosed according to World Health Organization criteria51.
We excluded individuals who were positive for antibodies against glutamic acid
decarboxylase and those with diabetes due to liver dysfunction, steroids and other
drugs that might raise glucose levels, malignancy or a monogenic disorder known
to cause diabetes.
Clinical characteristics of Stage-1and Stage-2 participants are shown in
Supplementary Table 24. Genomic DNA was extracted from peripheral leukocytes
using the standard procedure. All individuals provided written informed consent to
participate in this study. The protocol of this study conformed to the provisions of
the Declaration of Helsinki and was approved by the ethical committees at the
RIKEN Yokohama Institute and all other institutions.
Genotyping and quality control in the discovery stage. Set-1 samples were
genotyped using the Human Omni Express Exome Bead Chip. There were
535,686 autosomal SNPs that passed quality control, with a call rate Z0.99, for
Hardy–Weinberg equilibrium test P Z1 10 6 in controls and minor allele
frequency (MAF)Z0.01. Set-2 samples were genotyped using the Illumina Human
610K SNP array. There were 480,426 autosomal SNPs that passed quality control
and were used for further analysis. For sample quality control, we evaluated cryptic
relatedness for each sample using an identity-by-state method and removed
samples that exhibited second-degree or closer relatedness. We further performed
principal component analysis to select individuals within the major Japanese
(Hondo) cluster as reported previously5–7,52, and data for 16,580 individuals (9,817
T2D cases and 6,763 controls) in set-1 and 25,066 individuals (5,646 T2D cases and
19,420 controls) in set-2 were used in subsequent analyses. To evaluate the
potential effect of population stratiﬁcation, we used a quantile–quantile plot of the
observed P-values (Supplementary Fig. 1A,B).
Imputation. We performed genotype imputation using MACH and Minimac53,54
with individuals from the 1000 Genomes Project (phased JPT, CHB and Han
Chinese South data n¼ 275, March 2012) as reference populations55. We selected
SNPs with MAFZ0.01 and a Minimac software quality score (r2)Z0.7. Individual
genotype dosage data were used for association studies using mach2dat53,54.
Genotyping and quality control in the Stage-2 analysis. We genotyped 7,936
individuals with T2D and 5,539 controls using a multiplex PCR-Invader assay, as
described previously3,5–7. Genotyping success rates o95% or concordance rates
o99.9% were excluded from further evaluation.
Follow-up analyses. We obtained follow-up analysis data (n¼ up to 223,966:
65,936 T2Ds and 158,030 controls) from multiple cohorts or a publicly available
database, as described below.
East Asian populations. We obtained genotype data for up to 29,937 individuals
(12,554 T2Ds and 17,383 controls), de novo genotyping from 2 cohorts and in silico
replication data from 9 cohorts (Supplementary Table 9).
South Asian populations. We obtained in silico genotype data for a total of
up to 24,965 individuals (10,587 T2Ds and 14,378 controls) from 6 cohorts
(Supplementary Table 9).
European populations. We obtained genotype data for up to 160,850 individuals
(38,947 T2Ds and 121,903 controls), de novo genotyping data from the Danish
case–control study and from a publicly available database (DIAGRAM3 http://
diagram-consortium.org/downloads.html)10. The Danish case–control study
consisted of individuals from the Inter99 cohort56, Health2006 cohort57, Vejle
Biobank58, T2D cases from the Danish ADDITION screening cohort59 and a T2D
case–control study obtained at Steno Diabetes Center (SDC). Two SNPs were
genotyped by Illumina MetaboChip in 8,781 individuals from Inter99, Health2006
and SDC, whereas four SNPs were genotyped by LGC Genomics, UK, in
individuals from Inter99, Vejle Biobank, ADDITION and SDC samples
(Supplementary Table 9).
Mexican/Latino population. We obtained in silico genotype data for up to 8,214
individuals (3,848 T2Ds and 4,366 controls) from the SIGMA Type 2 Diabetes
Consortium (Supplementary Table 9).
Ethnicity was self-reported by the enroled individuals. For each study, approval
was obtained from the institutional review boards of the participating institutions
and written informed consent was obtained from all participants. We excluded
association data obtained by imputed genotyped data with a low quality of
imputation (r2o0.7 or info o0.7). Details of the study samples are described in
Supplementary Table 9.
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Statistical analysis. The association between each SNP and T2D was assessed
using the logistic regression test with an additive model with or without adjusting
for age, sex and log-transformed BMI. We combined data from the each GWAS
and our validation analyses using an inverse variance method and examined
heterogeneity with a Cochran’s Q test using METAL60. Regional association plots
were generated using LocusZoom61.
We also performed quantitative traits analysis for fasting plasma glucose,
HOMA-b and HOMA-IR using multiple linear regression analysis in an additive
association model with or without adjusting for age, sex and log-transformed BMI.
The Japanese samples studied here show skewed distribution values for BMI,
HOMA-IR and HOMA-b; therefore, we have analysed the quantitative traits using
log-transformed BMI, HOMA-IR and HOMA-b.
Drug discovery. We performed a search for potential drug targets using
genetic information of conﬁrmed T2D susceptibility loci and publicly available
bioinformatics tools29,30 and databases28,62–65 using a method that has been
previously described by Okada et al.27 (Supplementary Note).
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